[Skip to Content]
[Skip to Content Landing]
January 3, 1948


Author Affiliations

Washington, D. C.

From the Infectious Disease Service and the George Washington Medical Division, Gallinger Municipal Hospital, and the Departments of Pediatrics and Medicine, George Washington University.

JAMA. 1948;136(1):8-12. doi:10.1001/jama.1948.02890180010003

Previous studies from this hospital have endeavored to determine the value of various sulfonamide drugs in the treatment of meningococcic meningitis and to analyze certain factors which influence the prognosis of this disease.1 Although these studies have shown that the case-fatality rate in meningococcic meningitis could be lowered to approximately 10 per cent with the use of either sulfadiazine or sulfamerazine, it was felt that it might be possible to reduce the fatality rate still further. One way to do this, according to the opinion of some investigators,2 would have been to employ larger doses of sulfonamide compounds. Motivating against such a course, however, was the expectation that renal calculi would develop in more patients if the dose of sulfadiazine or sulfamerazine were increased.

The studies of Lehr3 suggested the possibility that larger doses of sulfonamide drugs could be used without raising the frequency of renal complications